working
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ 0.20? I don `t believe
we are strong, there is no rush
0.375 and...blue sky
IPIX
and 5 min before 63.486 to 0.32
paint? LOL LOL LOL
yes, very nice
IPIX
we're going to "dollar" land $$$
very strong
IPIX
no rush, loaded for over a year and adding below,
It is time for those who are outside to run
NEWS IPIX
we passed 23, 24, 25 ... 28, 29, 30, what is the next wall?
July 29, 2021 - 7:00 am
FORT LEE, N.J., July 29, 2021 -- Creatd, Inc. (Nasdaq CM: CRTD) ("Creatd" or the "Company"), the parent company of Vocal, today announced that it has entered into a non-binding Memorandum of Understanding ("MOU") to purchase a majority stake in direct-to-consumer company, Wobble Wedge®, which has disrupted the home improvement category with its eponymous, multi-patented product. Wobble Wedges®, sold through both direct-to-consumer (DTC) and wholesale avenues, are an interlocking modular system of tapered shims that are adaptable to hundreds of uses. The Wobble Wedge has become a staple tool for a wide range of user types, from homeowners to craftspeople, hobbyists, restaurant owners, plumbers, and more.
0.50$ coming
IPIX
0.50$ soon
because there will be a wall at 23, 24, 25, 26, 27 28 etc?
if we stay above $ 28.5 I think we will try again $ 0.50
a joy for all
LOL. and the MMS that are now priced below $ 28.7?
do we not take them into account? then they will be 28.7 or higher
Amprya is still doing better than expected and will rack up 75-85 of sales in the US 2021. Famprya is sold by Biogen in Europe and totaled 100 million in 2020. Inbrija has more challenges, but still totaled 24 million sales in 2020 and sales 35-38 in 2021 in the US And now, with the new contract from Spain and the approval of GBA rebates in Germany, Acorda is in an excellent position to negotiate with Biogen or others for other sales outside the US in other countries
could it finally be that the final date they set in Russia is correct?
at first I remember that it surprised everyone,
but let's not forget that 80% of the trial is in Russia,
http://grls.rosminzdrav.ru/CiPermitionReg.aspx?PermYear=0&DateInc=&NumInc=&DateBeg=&DateEnd=&Protocol=IPI-BRIc-201&RegNm=&Statement=&ProtoId=&idCIStatementCh=&Qualifier=&CiPhase=&RangeOfApp=&Torg=&LFDos=&Producer=&Recearcher=&sponsorCountry=&MedBaseCount=&CiType=&PatientCount=&OrgDocOut=2&Status=1%2c2%2c3%2c4&NotInReg=0&All=0&PageSize=8&order=allpatient&orderType=asc&pageNum=1
30/9/21 final date
https://asv.org/asv2021/sponsors-donors/
the list of sponsors and exhibitors is huge,
the repercussion will be very great
Nothing really important to say until the results of Phase 2, and it will be in August - September 1st,
Neither in the virology congress they will be able to reveal any data of the study
They will talk about the "benefits" of B, but they cannot reveal data, among other things because they do not know them either
"The FDA's oversight and the EU equivalent monitoring is what has given Russia the accolades and reason that worldwide Pharmas trust their Clinical Trial System. But that's just my opinion. IMO it was genius that Leo had the insight and foresight to utilize the Russian Clinical Trials system."
To date, Rusa has not managed to get its Sputnik vaccine approved by the European Medicines Agency, due to opacity of the data and lack of documentation at the request of the EU
What are they waiting for to heat this up a bit!
one month only for phase II results and virology conference
https://quantisnow.com/insight/1046468?s=s
Soon the price will pick up all the positive developments:
Biogen Royalties,
Sale of Manufacturing Operations to Catalent
Debt payment,
https://ih.advfn.com/stock-market/NASDAQ/acorda-therapeutics-ACOR/stock-news/85375189/current-report-filing-8-k
new target price $ 10
disconcerting, the results are approaching and neither pumping, nor heating etc. quite the opposite
now we will say: MM, manipulation ...
this is OTC and in the situation that is IPIX the OTC values "fly", many others do it out of nowhere
I still think that the test in Russia takes away interest
because in the US it is being tested with: four or five people?
but hey, we'll keep waiting
and me over 25$
we don't have volume
chart is ugly, ugly
all phase II is in Russia, only two sites in the US
Why?
creates mistrust?
we will have an update on clinicaltrials.gov, it appears that some US site has not started recruiting yet
very good ... sell your
tic tac 60 days
July or August is indifferent, we will have the end of the study and the important thing is that it is positive
Innovation Pharma Completes Enrollment in Phase 2 Clinical Trial for COVID-19
WAKEFIELD, MA – June 3, 2021 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that it has achieved full patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). Innovation Pharmaceuticals is developing Brilacidin for treatment of COVID-19 under U.S. FDA Fast Track designation.
Complete trial enrollment comprised 120 dosed patients recruited across multiple sites. Final data collection for the last patient enrolled in the study is expected to occur in early August (Study Day 60), which will then be followed by the process of unblinding study data and the reporting of topline study results.
“We are pleased to have reached this company milestone and particularly thank all of the participating investigator sites and patients, in addition to many others involved in supporting the completion of study enrollment, especially given the challenges brought on by the pandemic,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “Encouraged by extensive laboratory-based Brilacidin antiviral research focused on coronaviruses, and building on previous pre-clinical and clinical results demonstrating a robust Brilacidin therapeutic profile, we prioritized the development of Brilacidin as a novel antiviral. To us, this is much more than a COVID-19 study. Our goal is to develop a broad spectrum antiviral not just to help contain today’s pandemic, but also one that could be deployed against other infectious and deadly viruses that inevitably will follow. As such, we eagerly look forward to our Brilacidin COVID-19 trial readout.”
Based on pre-clinical studies, Brilacidin is exhibiting an ability to directly disrupt viral integrity, a potent virucidal property, enabling it to be unaffected by mutations that give rise to variants—a beneficial trait differentiating Brilacidin from other antivirals.
NOW, NEWSSSSSSSSSSSSS